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The newly observed nongenomic effects of glucocorticoids on signaling pathways
operating in neutrophils in vitro will stimulate further investigations on pathogenic
mechanisms and drug actions in bullous skin diseases.
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There is by far no other drug class that is
used so frequently by dermatologists
as glucocorticoids. Their use as either
topical or systemic anti-inflammatory
drugs is based on their ability to block
the expression of proinflammatory genes
and to induce the transcription of anti-
inflammatory genes (Rhen and Cidlowski,
2005). Besides these transcription-
dependent mechanisms, glucocorti-
coids can have rapid effects on
inflammation that are not mediated
by changes in gene expression. For
instance, the inhibition of vasodila-
tion and reduction in endothelial
permeability are believed to contribute
to the anti-inflammatory activity of
glucocorticoids (Rhen and Cidlowski,
2005). Other nontranscriptional mecha-
nisms may include decreased stability of
mRNAs of cytokine genes (Gille et al.,
2001). Furthermore, the activation of
caspases by glucocorticoids in eosino-
phils, but not neutrophils, has been
described (Meagher et al.,1996). There
is, however, little information regarding
the molecular mechanisms of these so-
called nongenomic pathways available.
Bullous pemphigoid (BP) represents
the most frequent autoimmune sub-
epidermal blistering disease, character-
istically associated with autoantibodies
directed against BP180 (also termed
BPAG2) and BP230 (BPAG1-e), two
components of junctional adhesion
complexes called hemidesmosomes
(Borradori and Sonnenberg, 1999).
Besides these autoantibodies, neutro-
phils have been shown to have a
critical role in BP (Liu et al., 1997).
In this issue of the Journal, Hellberg
et al. (2013) investigated the effects
of methylprednisolone on human
neutrophils as BP can be efficiently
treated with either topical or systemic
glucocorticoids (Joly et al., 2002).
The authors hypothesized that methy-
lprednisolone might directly block
neutrophil activation here (Figure 1).
Intriguingly, they observed in fact a
marked block of autoantibody-induced
activation of phosphatidylinositide
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3-kinase (PI3K), p38 mitogen-activated
protein kinase (MAPK), and extracellular
signal–regulated kinases 1/2 (ERK1/2)
in purified human neutrophils in vitro.
As these findings are provocative, the
authors have additionally demonstrated
that methylprednisolone, as well as
more or less specific inhibition of these
kinases by known pharmacological
inhibitors, could block the production
of reactive oxygen species (ROS) in acti-
vated neutrophils. Methylprednisolone
and the kinase inhibitors were also able
to prevent blister formation in both
ex vivo and in vivo BP models.
The activation of the nicotinamide
adenine dinucleotide phosphate
(NADPH) oxidase, the enzyme largely
responsible for ROS production in
neutrophils, has previously been shown
to require activation of pathways invol-
ving p38 and PI3K (Geering et al.,
2011). If methylprednisolone is indeed
able to pharmacologically inacti-
vate these kinases, under the in vitro
conditions used by the authors, it is
not surprising that it also blocks ROS
production by activated neutrophils.
It is, however, less clear that
neutrophil-derived ROS are required
for blister formation in BP. Moreover, it
should be noted that these authors used
whole leukocyte populations for their
ex vivo model. Therefore, it is unclear
whether the observed epidermal–dermal
separation was indeed mediated selec-
tively by neutrophils. The situation
in vivo is even more complex; it is
uncertain whether a potential inhibition
of PI3K, p38 MAPK, or ERK1/2 in
neutrophils is indeed the main effect
responsible for the prevention of blister
formation. In addition, it should be
noted that with these in vivo models
all inhibitors were given in a prophylac-
tic and not in a therapeutic manner,
suggesting that the initiation of the
inflammatory cascade was blocked,
including neutrophil infiltration.
Similarly, the question whether methyl-
prednisolone could reduce kinase acti-
vation of already-activated neutrophils
remains to be answered.
Besides these fundamental questions,
which need to be answered in future
studies, an additional note of caution
ought to be raised. The authors used
extremely high methylprednisolone
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concentrations (1mM) for blocking the
activation of PI3K, p38 MAPK, and
ERK1/2 in neutrophils. Inhibition of cyto-
kine gene expression is usually seen with
1–10mM. Unfortunately, as Hellberg
et al. (2013) did not demonstrate that
the observed effects were mediated
through the glucocorticoid receptor, the
question of specificity needs to be
answered. Moreover, one would like to
know what other kinases are blocked
by methylprednisolone, or, even more
important, which kinase(s) cannot be
blocked with high concentrations of
glucocorticoids in cells. Finally, direct
effects of glucocorticoids on human
neutrophils have been reported pre-
viously. For instance, neutrophils have
a prolonged in vitro life span in the
presence of relatively low concentra-
tions of glucocorticoids (Meagher et al.,
1996). Interestingly, and in sharp con-
trast to the data of Hellberg et al. (2013),
an early report suggested that gluco-
corticoids mediated this effect through
PI3K- and p38 MAPK–dependent path-
ways (Saffar et al., 2008). The activation
of PI3K by glucocorticoids has also been
reported in endothelial cells (Hafezi-
Moghadam et al., 2002), suggesting
that this mechanism may not be cell
type dependent. The reason of this
discrepancy may largely lay in the
different glucocorticoid concentrations
used in the different studies.
Taken together, although nongenomic
effects of glucocorticoids on signaling
pathways operating in neutrophils can
be observed under in vitro conditions, it
is important to test whether or not they
are glucocorticoid receptor mediated
and to demonstrate their physiological
relevance.
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Figure 1. Potential effects of methylprednisolone in bullous pemphigoid (BP). BP is characterized by
blister formation at the dermal–epidermal junction mediated by autoantibodies to collagen XVII (COL17)
and subsequent activation of inflammatory cells including neutrophils. Methylprednisolone inhibits signal
cascades responsible for reactive oxygen species (ROS) production in neutrophils upon activation by
immune complexes. Thus release of ROS and, perhaps, the release of elastase and MMP-9, known to cause
tissue damage, are blocked. In addition, it is likely that methylprednisolone reduces IL-8 expression,
resulting in reduced neutrophil recruitment to the inflammatory site. ERK, extracellular signal–regulated
kinase; MAPK, mitogen-activated protein kinase; PI3K, phosphatidylinositide 3-kinase.
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